Cesaro Simone, Cavaliere Mara, Spiller Monica, Rossi Lucia, Magagna Laura, Gavin Patrizia, Bonetto Michela, Carli Modesto
Clinic of Pediatric Hematology and Oncology, Department of Pediatrics, University of Padova, Via Giustiniani 3, 35128, Padova, Italy.
Support Care Cancer. 2007 Jan;15(1):95-9. doi: 10.1007/s00520-006-0099-5. Epub 2006 Jul 1.
We report a simplified method of performing antibiotic lock therapy (ALT) based on a disposable central venous catheter (CVC) hub device, CLC 2000, enabling an open-ended CVC to be flushed with normal saline solution without heparin.
ALT was administered through a CLC 2000 connector for recurrent CVC-bloodstream infections (BSI) by the same organism in four patients and for CVC colonization in five patients.
The antibiotic concentration obtained in the lumen of the CVC with ALT was 2,500-fold higher than the minimum inhibiting concentration of targeted bacteria for patients treated with vancomycin, 2,500-80,000-fold higher for patients treated with teicoplanin, and 10,000-fold higher for the patient treated with amikacin. All CVC-BSIs treated with ALT resulted in complete clinical and microbiological responses. No case of malfunction in withdrawing or flushing the CVC and no precipitation during the administration of the antibiotic solution was observed. No recurrence of CVC-BSI or CVC colonization by the same organism was diagnosed during subsequent follow-up, despite the fact that all patients had further periods of severe neutropenia. At the last follow-up, three CVCs had been removed for other infections (fever of unknown origin in two; fungemia in one), four CVCs had been removed at the end of therapy, and one CVC is still in situ 20 months after ALT.
In conclusion, a course of ALT is feasible in cancer patients with infected but much-needed CVCs before resorting to removal. The use of the CLC 2000 connector device simplifies the procedure for preparation and administration of ALT without compromising its efficacy.
我们报告了一种基于一次性中心静脉导管(CVC)接头装置CLC 2000进行抗生素封管治疗(ALT)的简化方法,该方法可使开放式CVC用生理盐水冲洗而无需肝素。
通过CLC 2000接头对4例由同一病原体引起复发性CVC血流感染(BSI)的患者以及5例CVC定植患者进行ALT治疗。
接受万古霉素治疗的患者,ALT治疗后CVC管腔内获得的抗生素浓度比目标细菌的最低抑菌浓度高2500倍;接受替考拉宁治疗的患者高2500 - 80000倍;接受阿米卡星治疗的患者高10000倍。所有接受ALT治疗的CVC - BSI均获得了完全的临床和微生物学缓解。未观察到CVC抽液或冲洗故障的情况,抗生素溶液给药期间也未出现沉淀。尽管所有患者随后均经历了严重中性粒细胞减少期,但在后续随访中未诊断出同一病原体引起的CVC - BSI复发或CVC定植。在最后一次随访时,3根CVC因其他感染(2例不明原因发热;1例真菌血症)已拔除,4根CVC在治疗结束时已拔除,1根CVC在ALT治疗后20个月仍在位。
总之,对于感染但又急需使用CVC的癌症患者,在考虑拔除之前进行一个疗程的ALT是可行的。使用CLC 2000接头装置简化了ALT的制备和给药过程,且不影响其疗效。